Group 1 - The core viewpoint of the news is that Weisi Medical has seen a stock price increase of 5.05%, reaching 46.98 CNY per share, with a total market capitalization of 4.499 billion CNY [1] - Weisi Medical, established on January 10, 2001, focuses on the research, production, and sales of rehabilitation medical devices, particularly in areas such as pelvic floor and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [1] - The company's revenue composition includes: magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), electrical stimulation products (8.42%), and others (3.28%) [1] Group 2 - From the perspective of fund holdings, Weisi Medical is a top ten holding of Huayin Fund Management, specifically in the Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056), which reduced its holdings by 15,000 shares to 75,000 shares, representing 4.13% of the fund's net value [2] - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund (001056) was established on March 27, 2015, with a latest scale of 90.1431 million CNY, achieving a year-to-date return of 18.8% and a one-year return of 11.21% [2] - The fund manager, Pang Wenjie, has been in position for 5 years and 202 days, with the fund's total asset scale at 18.4 million CNY, achieving a best return of 44.46% and a worst return of -46.46% during his tenure [3]

Group 1 - The core decision of the board meeting was to conclude certain fundraising projects and permanently allocate the surplus funds to working capital [3][18] - The board meeting was held on December 17, 2025, with all seven directors present, and the decision was unanimously approved [2][4] - The surplus amount from the concluded projects is 36.9774 million yuan, which will be used to enhance the efficiency of fund utilization and support daily operations [9][16] Group 2 - The concluded fundraising projects include the Rehabilitation Equipment Assembly and Debugging Project and the Information Technology Construction Project [9][11] - The total fundraising raised was approximately 1.155 billion yuan, with a net amount of about 1.063 billion yuan after deducting issuance costs [10] - The surplus funds were generated due to effective cost control and management during the project implementation, leading to lower expenditures than initially planned [13][14] Group 3 - The decision to use surplus funds for working capital is aimed at optimizing resource allocation and enhancing operational efficiency, aligning with the company's long-term development strategy [16][17] - The audit committee and sponsor institution both support the decision, confirming it does not harm the interests of shareholders and complies with relevant regulations [17][19]

（文章来源：证券日报） 证券日报网讯 12月17日晚间，伟思医疗发布公告称，公司第四届董事会第七次会议审议通过《关于部 分募投项目结项并将节余募集资金永久补充流动资金的议案》。 ...

每经头条（nbdtoutiao）——"太空快递"来了？全国首个民营飞船成功"上天"！背后公司创始人：正积 极开发"中型货运飞船"低成本产品 2024年1至12月份，伟思医疗的营业收入构成为：医疗器械占比95.03%，其他占比3.79%，其他业务占 比1.18%。 截至发稿，伟思医疗市值为43亿元。 每经AI快讯，伟思医疗（SH 688580，收盘价：44.72元）12月17日晚间发布公告称，公司第四届第七次 董事会会议于2025年12月17日在公司会议室召开。会议审议了《关于部分募投项目结项并将节余募集资 金永久补充流动资金的议案》等文件。 （记者 王晓波） ...

长江证券承销保荐有限公司关于 南京伟思医疗科技股份有限公司部分募投项目结项并将节余募 集资金永久补充流动资金的核查意见 注3：最终转入公司自有资金账户的实际金额以资金转出当日该项目募集资金账户余额 为准； 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上市公司募集资金监管规则（2025年6月15日起施行）》《上海证券交 易所科创板上市公司自律监管指引第1号——规范运作》等有关规定，作为南京 伟思医疗科技股份有限公司（以下简称"伟思医疗"或"公司"）首次公开发行股票 并科创板上市项目的保荐机构，长江证券承销保荐有限公司（以下简称"长江保 荐"或"保荐机构"）对公司部分募投项目结项并将节余募集资金永久补充流动资金的 事项进行了认真、审慎的核查，并出具核查意见。核查的具体情况如下： 一、募集资金基本情况 | 发行名称 | 2020年南京伟思医疗科技股份有限公司首次公开发行股票 | | --- | --- | | 募集资金总额 | 115,471.70万元 | | 募集资金净额 | 106,298.70万元 | | 募集资金到账时间 | 2020年7月15日 | 根据中国证券监督管理委员 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-043 南京伟思医疗科技股份有限公司 关于部分募投项目结项并将节余募集资金永久补充 流动资金的公告 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1213 号）文核准，公司向社会 公众公开发行人民币普通股（A 股）17,086,667 股，每股面值 1.00 元，每股发 1 行价格为 67.58 元。本次公开发行募集资金总额为 1,154,716,955.86 元，扣除 总发行费用 91,729,995.18 元（不含税），募集资金净额为 1,062,986,960.68 元。上述募集资金到位情况已经天衡会计师事务所（特殊普通合伙）审验，并于 2020 年 7 月 15 日出具了《验资报告》（天衡验字[2020]00075 号）。 注 1：康复设备组装调试项目节余募集资金金额包含累计收到的银行存款利 息扣除银行手续费的净额及购买理财产品收益共计 808.54 万元；信息化建设项 目项目节余募集资金金额包含累计收到的银行存款利息扣除银行手续费的净额 及购买理 ...

一、董事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第四届董事会第七次 会议通知于 2025 年 12 月 12 日以书面方式向全体董事发出。会议于 2025 年 12 月 17 日以现场结合通讯方式在公司会议室召开。 证券代码：688580 证券简称：伟思医疗 公告编号：2025-044 南京伟思医疗科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议由董事长王志愚先生召集并主持，会议应到董事 7 人，实到董事 7 人，公司全体高级管理人员列席了会议。本次会议的召集、召开程序符合《中华 人民共和国公司法》等相关法律、行政法规、规范性文件及《南京伟思医疗科技 股份有限公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于部分募投项目结项并将节余募集资金永久补充流动 资金的议案》 鉴于公司 IPO 时募投项目—康复设备组装调试项目、信息化建设项目基本建 设完毕并投入使用，同意公司予以结项，并将节余募集资金用于永久补充流动资 金。 特此公告 ...

Core Viewpoint - The company, Weisi Medical (688580.SH), has approved the conclusion of certain fundraising projects and plans to permanently supplement its working capital with the remaining funds from these projects [1] Group 1: Fundraising Projects - The company has decided to conclude the fundraising projects "Rehabilitation Equipment Assembly and Debugging Project" and "Information Technology Construction Project" [1] - The total remaining funds from these projects amount to 36.9774 million yuan [1] Group 2: Use of Remaining Funds - The remaining funds will be used to permanently supplement the company's working capital for daily operations and business development [1] - The actual amount used will be based on the balance of the fundraising account on the day of the fund transfer [1] - The company plans to cancel the fundraising account following this transfer [1]

证券日报网讯12月16日，伟思医疗在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东 总户数为8098户。 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, with a focus on specific companies such as Innovent Biologics, Efang Biologics, and Mindray Medical [4][27]. Core Insights - The report emphasizes the investment opportunities in the "One Old, One Young" sectors, particularly in reproductive assistance, pediatric drugs and vaccines, maternal and infant health monitoring, and aging-related consumer healthcare [2][24]. - It highlights the importance of clinical value in the pharmaceutical sector, suggesting that future investments should focus on innovative drug chains and high-end medical devices [3][25]. - The report notes that the domestic pharmaceutical sector is experiencing a valuation recovery, driven by supportive policies and increasing global competitiveness [26]. Summary by Sections Market Review - The A-share pharmaceutical index fell by 1.04%, underperforming the CSI 300 index by 0.96 percentage points and the ChiNext index by 2.52 percentage points, ranking 17th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index decreased by 2.26%, lagging behind the Hang Seng Index by 0.97 percentage points [1][15]. R&D Progress - Recent developments include IND applications from Haisimengnuo and clinical trial advancements for various drugs from companies like Hengrui Medicine and Anke Biotechnology [29][30]. Key Companies and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a positive outlook for companies like WuXi AppTec and Mindray Medical, with projected PE ratios decreasing over the next few years [4][27]. Policy and Industry Resonance - The report discusses the eight key tasks for medical insurance in 2026, focusing on improving coverage for flexible employment and enhancing maternal healthcare services, which are expected to boost the birth rate and the rehabilitation medical device industry [2][20][24]. Investment Strategy - The report suggests a three-stage investment strategy based on clinical value, recommending investments in innovative drugs and high-value medical devices, with a focus on companies that are expanding internationally [3][25][26].